The Medicines Co (MDCO: NASDAQ)
$34.48 1.06 | 3.17%
12/05/16 - 04:00 PM ET
979.20K / 1.34MVol / Avg. Vol:
33.98 / 33.42Open / Prev. Close:
33.98 - 35.32Today's Range:
27.5 - 43.7952 Wk Range:
Portfolios with MDCO
- Portfolio NameUser Type
- ContributorToxic Stocks for the Week E...
- ContributorStocks Rising On Unusual Vo...
- UserGFNN Stockdiagnostics 3
- ContributorStocks At New 52-Week Highs...
- ContributorBreakout Stocks Of The Week...
- UserSUPRATRADE Top 10 Small Cap...
- Userdarrylb Portfolio 1
- Usermiamirocksters Portfolio 1
- ContributorBarron's Research Reports 4...
- UserPART 3 JPMorgan 27th Annual...
Latest MDCO Headlines from TheStreet
- 10 Best Nasdaq Biotech Stocks in the Third Quarter 09.30.15 | 04:09 pm
- Medicines (MDCO) Stock Skyrockets Following Promising Cholesterol Drug Results 08.31.15 | 11:08 am
- Today's Weak On High Volume Stock: Medicines Company (MDCO) 07.29.15 | 10:07 am
- Strong On High Relative Volume: Medicines Company (MDCO) 07.06.15 | 10:07 am
- Will Medicines & Co. (MDCO) Stock be Hurt by Court Patent Ruling? 07.02.15 | 02:07 pm
- Medicines Company (MDCO) Marked As A Barbarian At The Gate 06.25.15 | 02:06 pm
- Insider Trading Alert - CLCT, MDCO And LQ Traded By Insiders 06.11.15 | 11:06 am
- First Week of January 2016 Options Trading For Medicines (MDCO) 05.19.15 | 11:05 am
- Insider Trading Alert - AMP, MDCO And MEMP Traded By Insiders 04.21.15 | 11:04 am
- Medicines Company (MDCO) Weak On High Volume 04.20.15 | 10:04 am
Press Releases for MDCO
- The Medicines Company Reports Second-Quarter And First-Half 2015 Financial Results - Business Wire 07.29.15 | 07:07 am
- The Medicines Company To Announce Second Quarter Financial Results On Wednesday July 29, 2015 - Business Wire 07.13.15 | 07:07 am
- The Medicines Company Authorizes Generic Launch Of ANGIOMAX® (bivalirudin) - Business Wire 07.09.15 | 08:07 am
- Federal Circuit Rules Against The Medicines Company In Angiomax® (bivalirudin) Patent Litigation - Business Wire 07.02.15 | 12:07 pm
- KENGREAL(TM)(cangrelor)(Photo: Business Wire) - Business Wire 06.22.15 | 03:06 pm
- Bios/Backgrounders - Business Wire 06.01.15 | 07:06 am
- The Medicines Company To Hold Conference Call On Tuesday, June 2 To Discuss Clinical Trial Results Of ABP-700 And MDCO-216 - Business Wire 06.01.15 | 07:06 am
- The Medicines Company Presents New Data Showing Remodeling Effect Of MDCO-216 On HDL Particles In Coronary Artery Disease Patients - Business Wire 05.26.15 | 10:05 am
- The Medicines Company To Participate In The Jefferies 2015 Healthcare Conference - Business Wire 05.22.15 | 07:05 am
- The Medicines Company To Participate In Bank Of America Merrill Lynch 2015 Health Care Conference - Business Wire 05.07.15 | 03:05 pm
Partner Headlines for MDCO
- Wainwright bullish on The Medicines Co's inclisiran, sees 65% upside in the stock - SeekingAlpha 12.05.16 | 04:12 pm
- The Medicines Co. initiated with a Buy at H.C. Wainwright - The Fly 12.05.16 | 07:12 am
- Clinical Analysis Of Alnylam's Next-Gen Lipid-Lowering Therapy - SeekingAlpha 11.21.16 | 12:11 pm
- Medicines Company's Should-Have-Been Day Falls Flat - SeekingAlpha 11.17.16 | 08:11 am
- Bay State Biotech Report: Medicines Co. and Alnylam - Bloomberg 11.16.16 | 09:11 am
- The Medicines Co. price target raised to $52 from $45 at RBC Capital - The Fly 11.16.16 | 08:11 am
- The Medicines Co. price target raised to $57 from $50 at Leerink - The Fly 11.16.16 | 08:11 am
- Alnylam selloff a buying opportunity, says Piper Jaffray - The Fly 11.15.16 | 01:11 pm
- Mid-stage safety profile of inclisiran spooks investors, MDCO down 6%, ALNY down 4% - SeekingAlpha 11.15.16 | 01:11 pm
- Motif Bio Reduces IPO Price To Entice Investors - SeekingAlpha 11.14.16 | 05:11 pm